Bruker Announces Pricing of Public Offering of Common Stock
May 29 2024 - 8:17PM
Business Wire
Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR)
today announced the pricing of its previously announced
underwritten registered public offering of 6,000,000 shares of its
common stock. Additionally, the Company has granted the
underwriters a 30-day option to purchase up to an additional
900,000 shares of its common stock. The offering is expected to
close on or about May 31, 2024, subject to market and other
customary closing conditions.
Bruker intends to use the net proceeds from the offering to
reduce indebtedness following its recent strategic acquisitions,
including to repay a portion of its outstanding borrowings under
the amended and restated revolving credit agreement dated as of
January 18, 2024.
BofA Securities and J.P. Morgan are acting as joint underwriters
and book-running managers for the offering. The underwriters may
offer the shares from time to time for sale in one or more
transactions on the Nasdaq Global Select Market, in the
over-the-counter market, through negotiated transactions or
otherwise at market prices prevailing at the time of sale, at
prices related to prevailing market prices or at negotiated
prices.
The offering is being made pursuant to an effective registration
statement on Form S-3 (including a preliminary prospectus
describing the terms of the offering) filed with the Securities and
Exchange Commission (the “SEC”) on May 29, 2024. A final prospectus
relating to the offering will be filed with the SEC and may be
obtained, when available, by contacting BofA Securities, Attention:
Prospectus Department, NC1-022-02-25, 201 North Tryon Street,
Charlotte, NC 28255-0001, or by email at
dg.prospectus_requests@bofa.com or J.P. Morgan, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or
by email at prospectus-eq_fi@jpmchase.com and
postsalemanualrequests@broadridge.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor is there any offer or sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Bruker Corporation – Leader of the Post-Genomic Era
(Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough
post-genomic discoveries and develop new applications that improve
the quality of human life. Bruker’s high-performance scientific
instruments and high-value analytical and diagnostic solutions
enable scientists to explore life and materials at molecular,
cellular, and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, improved productivity,
and customer success in post-genomic life science molecular and
cell biology research, in applied and biopharma applications, in
microscopy and nanoanalysis, as well as in industrial and cleantech
research, and next-gen semiconductor metrology in support of AI.
Bruker offers differentiated, high-value life science and
diagnostics systems and solutions in preclinical imaging, clinical
phenomics research, proteomics and multiomics, spatial and
single-cell biology, functional structural and condensate biology,
as well as in clinical microbiology and molecular diagnostics. For
more information, please visit www.bruker.com.
Forward-Looking Statements
This communication contains “forward-looking statements”
regarding the offering. All statements, other than statements of
historical fact, including statements regarding completion and
timing of the follow-on public offering, are forward-looking in
nature and are subject to risks, uncertainties and assumptions
about Bruker and its business, including, without limitation, risks
and uncertainties related to market conditions. Such
forward-looking statements involve substantial risks and
uncertainties that relate to future events and the actual results
could differ significantly from those expressed or implied by the
forward-looking statements. Any forward-looking statements are
based on Bruker’s current expectations, estimates and assumptions
regarding future events and are applicable only as of the dates of
such statements. Bruker makes no commitment to revise or update any
forward-looking statements in order to reflect events or
circumstances that may change, except as required by law. For
further discussion of these and other risks and uncertainties, see
Bruker’s most recent Form 10-K and Form 10-Q filings with the SEC.
Except as required by law, Bruker does not undertake any duty to
update forward-looking statements to reflect events after the date
of this press release. Readers are cautioned not to place undue
reliance on forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240529547540/en/
Justin Ward Sr. Director, Investor Relations & Corporate
Development Bruker Corporation T: +1 (978) 313-5800 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024